Format

Send to

Choose Destination
Eur Respir Rev. 2011 Mar;20(119):34-44. doi: 10.1183/09059180.00011010.

Lymphangioleiomyomatosis: what do we know and what are we looking for?

Author information

1
Unità Operativa di Pneumologia e Terapia Semi-Intensiva Respiratoria--Servizio di Fisiopatologia Respiratoria ed Emodinamica Polmonare Ospedale San Giuseppe, via San Vittore 12, Milan, Italy. sharari@ilpolmone.it

Abstract

Lymphangioleiomyomatosis (LAM) is a rare disease characterised by proliferation of abnormal smooth muscle-like cells (LAM cells) leading to progressive cystic destruction of the lung, lymphatic abnormalities and abdominal tumours. It affects predominantly females and can occur sporadically or in patients with tuberous sclerosis complex. This review describes the recent progress in our understanding of the molecular pathogenesis of the disease and LAM cell biology. It also summarises current therapeutic approaches and the most promising areas of research for future therapeutic strategies.

Comment in

PMID:
21357890
PMCID:
PMC3386525
DOI:
10.1183/09059180.00011010
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center